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Background—The use of lipid lowering agents is suboptimal among dual enrollees, particularly 
blacks.
Objectives—To determine whether the removal of restrictive drug caps under Medicare Part D 
reduced racial differences among dual enrollees with diabetes.
Research Design—An interrupted time series with comparison series design (ITS) cohort 
study.
Subjects—8,895 black and white diabetes ≥18 year old patients drawn from a nationally 
representative sample of fee-for-service dual enrollees (January 2004–December 2007) in states 
with and without drug caps before Part D.
Measures—We examined the monthly (1) proportion of patients with any use of lipid lowering 
therapies and (2) intensity of use. Stratification measures included age (<65, ≥65), race (white vs. 
black) and gender.
Results—At baseline, lipid lowering drug use was higher in no drug cap states (drug cap: 54.0% 
vs. non-drug cap: 66.8%) and among whites versus blacks (drug cap: 58.5% vs. 44.9%, no drug 
cap: 68.4% vs. 61.9%). In strict drug cap states only, Part D was associated with an increase in the 
proportion with any use [nonelderly: +0.07 absolute percentage points (95% CI: 0.06, 0.09), 
p<0.001; elderly: +0.08 (0.06,0.10), p<0.001] regardless of race. However, we found no evidence 
of a change in the white-black gap in the proportion of users despite the removal of a significant 
financial barrier.
Conclusions—Medicare Part D was associated with increased use of lipid lowering drugs, but 
racial gaps persisted. Understanding non-coverage-related barriers is critical to maximizing the 
potential benefits of coverage expansions for disparities reduction.
Introduction
Medicare beneficiaries who are simultaneously enrolled in Medicaid, also known as dual 
enrollees, represent less than 14% of the Medicaid population, but their care accounts for 
50% of total health care expenditures.1,2 More than one-third of dual enrollees have diabetes 
and, compared to other Medicare beneficiaries with diabetes, dual enrollees are more than 
twice as likely to be hospitalized for diabetes complications.1,3 Cardiovascular disease is the 
leading cause of morbidity and mortality in diabetes, making management of cardiovascular 
risk factors such as hyperlipidemia a critical component of diabetes management.4,5 Clinical 
guidelines recommend the use of lipid lowering agents for diabetes patients due to the 
potential for these agents to reduce adverse cardiovascular events.6 However, the use of 
these agents among dual enrollees with diabetes is suboptimal.7 Blacks, who are 
overrepresented among dual enrollees, have lower rates of use of lipid lowering drugs than 
whites despite being at increased risk for death from heart disease.1,7,8–11 Out of pocket 
costs for lipid lowering therapies have been identified as a significant barrier to guideline 
consistent treatment and as a potential determinant of disparities in use.12
Historically, coverage for lipid lowering and other prescription drugs was provided to dual 
enrollees through state administered Medicaid programs. The generosity of drug coverage 
through these programs has been highly variable, with several states (Texas, Oklahoma, 
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Mississippi, Arkansas) imposing restrictive caps on the number of reimbursable 
prescriptions per month.13–17 Drug caps have been associated with lower medication use 
and increase adverse events in vulnerable populations.18–21 The Medicare Modernization 
Act of 2003 required all dual enrollees to transition from Medicaid drug coverage to 
Medicare Part D, which disallowed the use of strict drug caps.22,23 Blacks are 
overrepresented among dual enrollees transitioning from Medicaid to Medicare Part D and 
are less likely to report having access to needed prescription medications under Part D.24 
Yet the impact of this major change in coverage for dual enrollees with diabetes on access to 
cardioprotective lipid lowering therapies and disparities in the use of these agents is 
unknown.
Using the implementation of Medicare Part D as a natural experiment, we compared 
changes in the use of lipid lowering therapies among black and white dual enrollees living in 
states with and without restrictive drug caps. We hypothesized that the introduction of Part 
D would be associated with an increase in the use of lipid lowering therapies. In addition, 
based on findings from an earlier pre post analysis of changes in overall medication use the 
Medicare population, we anticipated greater response among black dual enrollees,25 
resulting in a reduction in racial disparities in treatment in drug cap states. While this paper 
focuses on the impact of this transition on January 1, 2006, such transitions are ongoing 
since disabled Medicaid beneficiaries who become eligible for dual Medicare enrollment 
after a required two-year waiting period and Medicaid beneficiaries who age into Medicare 
are automatically switched from Medicaid to Part D drug coverage.22,23 Therefore, findings 
from this analysis have the potential to inform strategies to facilitate the smooth transition of 
dual enrollees from Medicaid to Part D going forward. Moreover, the identification of 
potential differences in response to coverage changes by race have relevance to current 




We used an interrupted time series with comparison series (ITS) cohort design to examine 
changes in use of lipid lowering drugs 24 months before and after the transition of dual 
enrollees from Medicaid to Medicare Part D drug coverage. As Part D affected all dual 
enrollees, there is no natural control group. Therefore, we exploited natural variation in the 
existence of drugs caps in state Medicaid programs to identify comparison groups of states 
based on exposure to drug caps before the introduction of Part D and heterogeneity of policy 
response among racial subgroups within strict drug cap and no drug cap states, respectively. 
We used longitudinal baseline data to allow each subgroup to act as its own control, 
comparing utilization after Part D to what we would have predicted in the absence of Part D, 
drawing on stable baseline trends. Assuming that state residency, while not random, is 
unrelated to the use of lipid lowering therapy among diabetes patients, this natural 
experimental design should provide strong evidence of Part D effects.
Our study protocol was reviewed and approved by the Institutional Review Board of the 
Kaiser Foundation Research Institute.
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Data Sources and Study Population
Using a merged dataset of a 5% nationally representative sample of linked Medicaid, 
Medicare, and Part D drug event standard analytic files for dual enrollees for the years 2004 
through 2007 obtained from the Centers for Medicare and Medicaid Services, we identified 
fee-for-service beneficiaries who were at least 18 years old in 2004 and who had at least one 
hospital diagnosis or two physician diagnoses (no more than 12 months apart) of diabetes 
(ICD9: 250.XX) at any time during the study period (2004–2007). (Figure 1) We excluded 
enrollees residing in Ohio, Arizona, and Louisiana due to data anomalies in those states such 
as concurrent changes in coding and reporting methods.26 The resulting study population 
included 60,288 adults with diabetes dually enrolled in fee-for-service (i.e., excluding 
managed care) Medicaid and Medicare.
We further required continuous enrollment for at least 10 months per year in both Medicaid 
and Medicare during the study period (n=29,373) and no more than 90 consecutive days in 
any year in an institution such as a nursing home (n=22,774; representing more than 455,000 
dual enrollees nationwide).
State Restrictions on Prescription Drug Reimbursement before Part D
We assigned strict drug cap status to four states (Texas, Oklahoma, Mississippi, Arkansas) 
that consistently limited monthly drug coverage to five or fewer total prescriptions or to 
three or fewer brand name drugs during the 24-month baseline period 2004–2005 and had 
no evidence of overrides or exceptions based on published summaries of drug 
benefits.14–18,27,28 To reduce possible misclassification, we excluded from analysis 11 states 
(AL, CA, GA, IL, KS, KY, ME, NC, NY, PA, SC) where true exposure to drug caps was 
difficult to ascertain due to higher cap thresholds and generous waiver policies. In addition, 
we excluded Tennessee, which instituted a strict drug cap late in the baseline period.15
We identified a comparison subgroup of dual enrollees who lived in 31 states (AK, CO, CT, 
DE, FL, HI, IA, ID, IN, MA, MD, MI, MN, MO, MT, ND, NE, NH, NJ, NM, NV, OR, RI, 
SD, UT, VA, VT, WA, WI, WV, WY) and the District of Columbia where there was no 
evidence of a prescription drug cap during the 24-month baseline period. Our final cohort 
for analysis included 8,895 black and white diabetes patients living in either strict drug cap 
or no drug cap states.
Outcomes
Our primary outcomes were (1) the monthly proportion of patients with any use of lipid 
lowering therapies (statins, niacin, bile-acid resins, fibric acid, derivatives, cholesterol 
absorption inhibitors) and (2) the intensity of use of these medications as represented by 
standardized monthly doses, a validated measure used in previous policy evaluation 
studies.19,21,22 We spread the days’ supply of each lipid lowering medication over the days 
following each dispensing; overlapping dispensing of the same medication was 
concatenated. We then created monthly indicators of any use for each patient based on the 
availability of a given medication on one or more days in a month, and we used these 
patient-specific measures to calculate monthly prevalence of use in each patient subgroup.
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To assess intensity of use, we first defined a standardized monthly dose (SMD)19,22 for each 
generic entity of interest, which was equal to the median number of milligrams dispensed 
per month across person-months with any use during the entire study period. Thus, SMDs 
represent the population’s “typical” monthly dose for a given medication. We then 
calculated average SMDs per patient per month (for specific drugs and by class) in order to 
evaluate changes in population intensity of use of lipid lowering agents over time, 
controlling for changes in prescription size. A key advantage of the SMD measure is that it 
allows for comparisons in the intensity of use across unique drug entities.
Policy Variables
We controlled for prior trends in the outcomes of interest using segmented time series 
regression, as described in previous studies.19–22,29 We included a dichotomous indicator for 
months before and after Part D implementation, as well as a variable to estimate changes in 
after-Part D trends. We identified state drug cap status in 2005 (strict drug cap vs. no drug 
cap) using a dichotomous indicator. Variation in Part D effect by drug cap status was 
evaluated by stratifying on the cap indicator and exploring interactions between it and the 
two Part D variables described above.
Covariates
We used Medicare administrative files to determine racial identity, age, and gender. Given 
higher rates of long-term disability among younger dual enrollees, we stratified all analyses 
by age: aged 65 or older (elderly) versus 18–65 years of age (non-elderly). Race and 
ethnicity data in these files are generated from Social Security Administration records based 
on social security card applications. Before 1980, the only options for race categorization 
were “white,” “black,” and “other,” resulting in low and inaccurate capture of data on 
Hispanics and other racial and ethnic groups.30 While geocode- and surname-enhanced race 
and ethnicity data are now available to link to the 5% sample, these enhancements were not 
available throughout our study period.31 Therefore, we included only patients with race 
designated as white or black, which are highly sensitive and specific.30
To compare underlying health status across subgroups at baseline, we created patient-
specific comorbidity scores using the hierarchical chronic conditions method employed by 
the Centers for Medicare and Medicaid Services for risk adjustment and service claims from 
2005.32 We also calculated the proportions of patients in each subgroup that year who had at 
least one hospital or two physician claims with a diagnosis of hypertension, and hospital 
claims related to diabetes, stroke, and ischemic heart disease.
Statistical Analysis
We used interrupted time series with comparison series to evaluate changes in the level and 
slope of the drug utilization outcomes, controlling for baseline trends.33 We first estimated 
the overall impact of transitioning to Part D by cap status using separate ITS models for the 
nonelderly and elderly subgroups in both strict drug cap states and in the comparison group 
of no drug cap states, separately. We did not control for prior cardiovascular risk factors 
because lipid lowering therapy is recommended for all diabetes patients over 40 years old.6
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Our data indicated a period of instability during the month before and three months 
following implementation of Part D, which may reflect anticipatory policy effects, data 
anomalies or some combination of factors that have the potential to bias study results. 
Therefore, we excluded observations generated during this brief, four-month transition 
period (i.e., December 2005–March 2006) from the models. The units of analysis were state-
months, with 4 strict drug cap status states (“treatment”) and 32 no drug cap 
states(“comparison group”) and monthly data from 23 pre-2006 months and 21 post 2006 
months, leading to 44 observations (23 +21) in each group where the model is fitted. Our 
time series models controlled for autocorrelation by testing for first-order autoregressive 
processes and correcting for significant correlations. We also tested for non-linearity of the 
models.33
We directly evaluated the impact of Part D on racial gaps in the use of lipid lowering drugs 
by modeling month-to-month white-black differences in use.34 We stratified these ITS 
models by age, but not for cardiovascular risk as in the main models. Given higher levels of 
cardiovascular related disease among blacks at baseline, our models should represent 
conservative estimates of disparities. We then show the estimated white-black difference in 
the outcomes of interest at one year post intervention (April 2007) relative to what we would 
have expected based on prior trends. For models indicating evidence of an interaction 
between race and the policy effect variables, we further conducted race and age stratified, as 
well as race, age and gender stratified models to explore the nature of the interaction.
To account for multiple testing, we applied a Bonferroni correction to reduce the likelihood 
of false positives.35 For analyses of Part D impact overall and analyses of changes in the 
white-black gap, we conducted eight independent tests and p values of 0.006 or smaller were 
considered statistically significant. For race, age and gender stratified models, we used a cut 
off of 0.004 to evaluate statistical significance to account for 12 independent tests. All 
statistical analyses were conducted using the SAS system (SAS, v.9.0, Durham, NC).36
Results
Enrollee Characteristics
We identified 8895 black and white dual enrollees with diabetes living in strict drug cap 
(2175) and no drug cap states (6720) who met our study criteria (Table 1). Compared to dual 
enrollees living in no drug cap states prior to Part D, dual enrollees in strict drug cap states 
were more likely to be black, non-elderly, and female. The proportions of dual enrollees 
using diabetes-related medications were similar across the two groups with the exception of 
use of insulin (drug cap: 28.4% vs. no drug cap: 32.1%) and lipid lowering agents (drug cap: 
54.0% vs. non-drug cap: 66.8%), both of which were more commonly used by dual 
enrollees in states without drug caps. In addition, dual enrollees in strict drug cap states were 
more likely to have comorbid hypertension (66.9% vs. 57.5%).
Within strict drug cap states (Table 1), blacks were more likely than whites to be nonelderly, 
female, using insulin, any diabetes medication, have hypertension, and to be on 
antihypertensives. In no drug cap states, blacks were more likely to be elderly, female, have 
higher levels of comorbidity, including hypertension, to use diabetes and antihypertensive 
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drugs and to have higher rates of hospitalization for ischemic heart disease and stroke. 
However, use of lipid lowering therapy was higher among whites compared to blacks in 
both strict drug cap (whites: 59.5%; blacks: 44.9%) and no drug cap states (whites: 68.4%; 
blacks: 61.9%).
Changes in Use of Lipid-Lowering Medications in Strict Drug Cap versus No Drug Cap 
States
Figure 2 shows time series of changes in the proportion of dual enrollees using lipid 
lowering therapies in strict and no drug cap states before and after Part D implementation. 
Among both nonelderly and elderly dual enrollees with diabetes living in strict drug cap 
states, the transition from Medicaid to Medicare Part D was associated with significant 
increases in the proportion of patients using lipid lowering medications [nonelderly: 0.07 
absolute percentage points (95% CI: 0.05, 0.09), p<0.001; elderly: 0.08 (0.05,0.10), 
p<0.001]. (Table 2) There was also an increasing trend in the proportion of patients with any 
use overtime in both age groups. In contrast, there were no statistically significant level 
shifts in use at the time of Part D implementation among those living in no drug cap states 
[nonelderly: −0.001 (−0.01, 0.01), p=0.749; elderly: −0.01 (−0.03, 0.01), p=0.205].
Similarly, the introduction of Part D was associated with increased intensity of use of lipid 
lowering medications among both non-elderly and elderly dual enrollees in strict drug cap 
states [nonelderly: 0.09 SMDs (0.03, 0.14), p=0.002; elderly: 0.08 (0.03, 0.12), p=0.002] but 
not in no drug cap states [nonelderly: −0.01 (−0.03, 0.005); p=0.144; elderly: 0.002 (−0.02, 
0.03), p=0.842]. In addition, no drug cap states had a statistically significant (p<0.001) 
decreasing trend in both the proportion of users [nonelderly: −0.004 (−0.005, −0.003); 
elderly: −0.004 (−0.005, −0.002)] and in the intensity of use [nonelderly: −0.004 (−0.01, 
−0.003); elderly: −0.01(−0.01 −0.004)] of lipid lowering agents.
Racial Differences in Changes in Use of Lipid-Lowering Medications after Part D
The results of models estimating the white-black gap in use of lipid lowering medications, as 
well as estimated white-black differences in use at 12 months post-policy implementation 
(April 2007) relative to what would have been expected given prior trends are presented in 
Table 3. ITS models of monthly white-black differences did not produce statistically 
significant evidence of a change in the racial gap in the proportion of users, regardless of 
state drug cap status. We did, however, observe a slight, statistically significant declining 
trend in the white-black gap in the intensity of use post Part D among dual enrollees living 
in no drug cap states [nonelderly white-black gap: −0.004 (−0.01, −0.002), p<0.001; elderly 
white-black gap: −0.005 (−0.007, −0.002), p<0.001)].
Age-race stratified models of SMD for patient in no cap states (see Table, Supplemental 
Digital Content 1) suggest that the primary driver of this change was a declining trend 
among whites [nonelderly: −0.005 (−0.01, −0.004); elderly: −0.01 (−0.01, −0.005)]. We 
further observed a small, statistically significant decrease in the level of intensity of use 
among non-elderly blacks [−0.04 (−0.06, −0.02); p=0.001] in no drug cap states, that was 
not observed among whites. Further stratification by gender revealed that while the 
declining trend among whites was not gender specific, among blacks, only non-elderly men 
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exhibited a declining trend in the intensity of use post-policy [−0.005 (−0.01, −0.003); 
p<0.001)]. In addition, the observed decrease in the level of intensity of use at the time of 
the policy among non-elderly blacks was primarily driven by changes among non-elderly 
black women [−0.04 (−0.07, −0.02);p=0.003].
Conclusions
Among fee-for-service dual enrollees with diabetes living in strict drug cap states with 
partial drug coverage, we found that the implementation of Part D was associated with 
abrupt increases in utilization of potentially life-saving lipid lowering medications compared 
to baseline trends that were not present in states without caps. In addition, we observed a 
sudden flattening of the upward baseline trend in the use of lipid lowering therapy among 
dual enrollees in no cap states. These findings differ from previously published studies,37,38 
which show no effect or minimal effects of Part D among dual enrollees. However, these 
prior studies did not adjust for state-level variation in the generosity of Medicaid coverage 
prior to Part D, which may have masked pockets of pent-up demand39 within the larger 
population of patients. This pent-up demand effect may be stronger in our study due to the 
focus on lipid lowering drugs, medications for which there is strong evidence of cost-related 
underuse and that are considered clinically essential medications for most adult patients with 
diabetes.11 Slight declining trends in the use of lipid lowering agents among dual enrollees 
in no cap states may be related to other changes in coverage related to Part D that were not 
the focus of this particular study. Specifically, those transitioning to private Part D plans 
from Medicaid may have faced other, somewhat less restrictive, forms of utilization 
management not addressed in this study (e.g., prior authorization, copayments).23
To our knowledge, this is one of the first studies to evaluate the impact of transitioning from 
Medicaid to Medicare Part D on disparities in use of clinically essential services. The 
removal of drug caps under Medicare Part D was not associated with an immediate 
narrowing of racial differences in the use of lipid lowering therapy in strict cap states as we 
had hypothesized. Instead, we observed a declining trend in differences in the intensity of 
use among those in no drug cap states, particularly among whites regardless of gender or 
age. The decrease in the level of intensity of use among non-elderly black women in no drug 
cap states was also unexpected. However, these changes were relatively small in magnitude, 
potentially limiting their clinical significance.
Our findings in drug cap states suggest that disparities in essential medication use in this 
population may be due to factors other than coverage, such as racial differences in beliefs 
about the benefits and potential harms of therapy, differences in quality of care or 
prescribing practices across settings, overall medication burden due to higher rates of 
comorbid hypertension or differences in trust and patient engagement, including use self-
management support services.40 However, evidence of racial difference in response to the 
policy in no drug cap states were surprising and may be related to other aspects of Part D 
such as changes in exposure to prior authorization and other administrative cost containment 
strategies or unobserved co-occurring policies in these states.
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While this study focuses on patient utilization of lipid lowering therapy, it is important to 
note that differential response to the policy by race may also reflect variation in physician 
response to policy change. In their role as prescribers, physicians can change prescribing 
practices in an effort to take advantage of expansions in coverage or to avoid administrative 
barriers to medication use. Yet, prior evidence suggests that physicians may be less likely to 
prescribe statins for black relative to white patients.41 By extension, variation in physician 
advocacy based on patient characteristics such as race or characteristics of the settings where 
minority patients receive care may have contributed to the lower rates of beneficial policy 
effects in vulnerable population subgroups. More studies using data on prescribing 
physicians, settings of care, and patient reported outcomes are needed to fully understand 
this and other potential drivers of heterogeneity in policy effects by race.
Several limitations deserve discussion. First, because all dual enrollees transitioned to Part D 
in January 2006, no true control group exists, which precludes a direct comparison of the 
effect between state drug cap subgroups, which varied considerably in underlying 
population characteristics at baseline. In addition, our decision to include only continuously-
enrolled patients in order to increase the stability of the underlying population also resulted 
in reduced generalizability of our findings to dual enrollees who move in and out of 
coverage.
A disadvantage of the ITS modeling strategy is that we could not control for confounders 
that occurred simultaneously with the policy, which are the only potential confounders of 
ITS designs.33 We assumed that sudden changes in population level characteristics such as 
severity of illness were highly unlikely. However, we could not control for unobservable 
local policy changes at the time of Part D implementation (e.g., state level efforts to educate 
Medicaid patients about the policy).
Our analysis of disparities is limited by the inaccuracy of racial and ethnic identifiers. 
Specifically, due to limited validity and reliability of race and ethnicity data during the study 
period,31,32 we excluded subgroups other than blacks and whites and did not further subset 
these groups by Hispanic ethnicity. Therefore, our analyses may mask subgroup differences 
based on ethnicity and do not necessarily extend to other racial groups that were excluded 
from this study.
Using a natural experiment, we found strong evidence that eliminating drug caps was 
associated with increasing the level and intensity of use of lipid lowering agents among 
vulnerable dual enrollees with diabetes. However, racial disparities in the use of these agents 
persisted post Part D despite the removal of a significant coverage related barrier to 
treatment. Targeted interventions to address non-coverage-related barriers to the use of lipid 
lowering therapy among blacks may be a necessary adjunct to ongoing policy level efforts to 
reduce access related treatment disparities in this highly vulnerable population. Additionally, 
while the selected study design provided strong evidence of differential effects by race, age 
and gender, alternative mixed methods designs may be needed to explore the contextual 
factors that drive variation in policy response.
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Figure 2. Time Series of the Proportion with Any Use of Lipid Lowering Medications, 2004–2007
A.) Non-eldery (Age < 65)
Strict drug cap states
Actual proportion of users, solid black circles
Estimated proportion of users per month, solid black line
Projected proportion of users per month, dotted black line
B.) Elderly (Age ≥ 65)
No drug cap states
Actual proportion of users, solid grey circles
Estimated proportion of users per month, solid grey line
Projected proportion of users per month, dotted grey line
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